The NICE technology appraisal group within HEDS – ScHARR-TAG – has had it’s next set of appraisals agreed with the NIHR. These include two STAs and a non-NICE Short Report. They are:
Degarelix (Firmagon, Ferring Pharmaceuticals) for the treatment of advanced hormone-dependent prostate cancer (STA)
Bevacizumab (Avastin, Roche) for the adjuvant treatment of triple negative early breast cancer (STA)
Sexual health of people with severe mental health illness (Short Report)
